Development of highly efficacious targeted therapeutics in the form of BCR::ABL1-specific TKIs has revolutionised the treatment of CML, leading to a more than 10-fold increase in survival for CML patients without the associated toxicities of alloHSCT. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.